|
Dynavax, AstraZeneca Amend Deal for Asthma Candidate
Zacks.com As per the amended agreement, AstraZeneca will now be responsible for conducting a phase IIa safety and efficacy trial on candidate AZD1419 in asthma patients. The study was originally decided to be conducted by Dynavax. The companies had earlier … |
View full post on asthma – Google News